ArticleCureus2025
A Rare Non-smoking-Related Spindle Cell Carcinoma of the Lung: A Case Report.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This paper introduces the case of a 30-year-old female diagnosed with pulmonary spindle-cell carcinoma (PSCC), a rare non-small cell lung carcinoma, with no history of tobacco use or any other known risk factors. The patient, with a diagnosis of neurofibromatosis type 1, showed symptoms of night fevers, thoracic pains, and massive pleural effusion, which led to a series of diagnostic studies, including imaging studies, biopsies, and immunohistochemistry analyses. The results from the pulmonary biopsy were used to make the definitive diagnosis of PSCC with negative results for the typical markers for this type of cancer. Following the diagnosis, the patient started a chemotherapy regimen consisting of doxorubicin and ifosfamide, with which she has survived for more than six months, despite the poor prognosis associated with PSCC. This case report highlights the rarity of this histological subtype, the difficulty in its diagnosis and management, the importance of completing a comprehensive diagnostic approach, and the need for further studies to improve the prognosis of these patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.